Iman Daryaei serves as the Co-Founder and CEO of TheraCea Pharma, a pioneering biotechnology company dedicated to advancing the field of diagnostic imaging through the development of Positron Emission Tomography (PET) agents. With a robust foundation in chemical synthesis and biological chemistry, Iman leverages his...
Iman Daryaei serves as the Co-Founder and CEO of TheraCea Pharma, a pioneering biotechnology company dedicated to advancing the field of diagnostic imaging through the development of Positron Emission Tomography (PET) agents. With a robust foundation in chemical synthesis and biological chemistry, Iman leverages his extensive industry experience and advanced training in molecular imaging techniques, including PET, Ultrasound, and MR Imaging, to facilitate innovative solutions for the diagnosis and treatment of cancer and neurological disorders.
Under his leadership, TheraCea Pharma is at the forefront of translating cutting-edge research into market-ready products, a passion that stems from his doctoral work at the University of Arizona. Iman's expertise in bioconjugate chemistry and drug discovery is instrumental in driving key projects aimed at enhancing patient selection and therapy assessment in oncology and neurology. His strategic vision not only focuses on the scientific aspects but also encompasses business analysis and organizational leadership, ensuring that the company remains agile and responsive to the rapidly evolving biotech landscape.
Iman's commitment to innovation is complemented by his strong public speaking skills, allowing him to effectively communicate the value of TheraCea's groundbreaking technologies to stakeholders and potential investors. His entrepreneurial spirit and dedication to improving patient outcomes through advanced diagnostic tools position TheraCea Pharma as a leader in the biotechnology sector, with a promising future in the realm of cancer immunotherapy and beyond.
